Antivirals

FDA Accepts Genentech’s New Drug Application for Xofluza for the Treatment of Influenza in Children

Friday, March 27, 2020 - 6:00am

Todays milestone brings us closer to providing single-dose Xofluza to children with influenza, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.

Key Points: 
  • Todays milestone brings us closer to providing single-dose Xofluza to children with influenza, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.
  • We also look forward to working with the FDA to incorporate Xofluza as a preventive treatment following exposure to influenza.
  • Xofluza tablets are currently approved in many countries around the world for the treatment of influenza types A and B.
  • BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza.

Feinstein Institutes begins enrolling patients in multiple COVID-19 clinical trials

Friday, March 20, 2020 - 2:33pm

The Feinstein Institutes for Medical Research , the research arm of Northwell Health, announced today the enrollment of three clinical trials in the ongoing effort to combat COVID-19, the novel coronavirus.

Key Points: 
  • The Feinstein Institutes for Medical Research , the research arm of Northwell Health, announced today the enrollment of three clinical trials in the ongoing effort to combat COVID-19, the novel coronavirus.
  • The three Feinstein Institutes trials are offered to patients already admitted to Northwell Health hospitals with moderate to severe COVID-19.
  • While there is a nationwide push for an expedited Food and Drug Administration (FDA) approval process of these and other experimental COVID-19 therapies, Northwell Health and the Feinstein Institutes prioritize the safety of patients.
  • With Gilead, the Feinstein Institutes will conduct two trials looking at the safety and efficacy of remdesivir (RDV), an investigational antiviral drug, designed to reduce the intensity and duration of COVID-19 in hospitalized patients.

DGAP-News: Abivax 2019 Financial Results and Operations Update

Monday, March 16, 2020 - 7:01pm

The observations confirmed the preliminary positive results on safety and tolerability of ABX464 along with a first evidence of its excellent long-term efficacy.

Key Points: 
  • The observations confirmed the preliminary positive results on safety and tolerability of ABX464 along with a first evidence of its excellent long-term efficacy.
  • Based on the encouraging results from the Phase 2a induction and maintenance trials, Abivax initiated a Phase 2b study, ABX464-103, in UC and enrolled the first patient in August 2019.
  • Top line results from this trial are expected in Q4 2020.
  • Abivax is currently planning for a start of the enrollment of patients in the second half of 2020.

Investment Experts discuss “Coronavirus Stocks” in an interview with Wall Street Reporter

Tuesday, February 25, 2020 - 6:30pm

WallStreetReporter.com also features the latest CEO Interview with Dr. Nader Pourhassan, CEO of CytoDyn, Inc. (OTC: CYDY) discussing Leronlimab as a Coronavirus treatment.

Key Points: 
  • WallStreetReporter.com also features the latest CEO Interview with Dr. Nader Pourhassan, CEO of CytoDyn, Inc. (OTC: CYDY) discussing Leronlimab as a Coronavirus treatment.
  • CytoDyn was a recent presenter at Wall Street Reporters NEXT SUPER STOCK conference.
  • A few of the biotech stocks he is currently focused on include, Gilead (GILD) andEmergent Biosolutions Inc. (EBS) which are attracting investor attention because of their relation to Coronavirus.
  • Gilead entered the spotlight recently with its antiviral Remdesivir, which is in clinical trials in China, as a possible treatment for the coronavirus.

Patents Must Not Block Coronavirus Treatment

Thursday, February 20, 2020 - 6:35pm

Gilead has been waiting for patent approval for remdesivir in China since 2016.

Key Points: 
  • Gilead has been waiting for patent approval for remdesivir in China since 2016.
  • The last thing this outbreak response needs is a battle over patents for a drug that, at least in these early stages, appears to have some success against this coronavirus, said AHF President Michael Weinstein.
  • Researchers all over the world are scrambling to find a cure that should remain the focus not strategizing for more profits using patents that could potentially limit access to an effective treatment.
  • Big pharma can fight it out after were positive this virus has been stamped outnow is not the time.

Chinese Scientist Unite Together to Tackle With COVID-19

Tuesday, February 18, 2020 - 5:08pm

Recently, some important achievements from these projects have already been implemented in the front line of epidemic prevention and control.

Key Points: 
  • Recently, some important achievements from these projects have already been implemented in the front line of epidemic prevention and control.
  • As a consequence, they discovered potentially effective anti- coronavirus drugs, such as Chloroquine Phosphate, Remdesivir, and Favipiravir.
  • "The positive curative effect has been shown in treating COVID-19," said Zhang Boli, the project leader and the headmaster of Tianjin University of Traditional Chinese Medicine.
  • Several new type of vaccines for COVID-19 have started the animal testing phase, which bring hope to all.

Chinese Scientist Unite Together to Tackle With COVID-19

Tuesday, February 18, 2020 - 3:44pm

Recently, some important achievements from these projects have already been implemented in the front line of epidemic prevention and control.

Key Points: 
  • Recently, some important achievements from these projects have already been implemented in the front line of epidemic prevention and control.
  • As a consequence, they discovered potentially effective anti- coronavirus drugs, such as Chloroquine Phosphate, Remdesivir, and Favipiravir.
  • "The positive curative effect has been shown in treating COVID-19," said Zhang Boli, the project leader and the headmaster of Tianjin University of Traditional Chinese Medicine.
  • Several new type of vaccines for COVID-19 have started the animal testing phase, which bring hope to all.

Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications

Thursday, February 13, 2020 - 5:56pm

The threat from the novel coronavirus outbreak has recently prompted the China National Health Commission to formally recommend the use of anti-AIDS drugs and inhalable interferon.

Key Points: 
  • The threat from the novel coronavirus outbreak has recently prompted the China National Health Commission to formally recommend the use of anti-AIDS drugs and inhalable interferon.
  • This has brought renewed attention to the importance of delivering interferon in a safe and effective manner to treat Covid-19 and other various viral indications not just in China, but globally.
  • Interferon and its various sub-types are key modulators in our innate immune response to viral infection.
  • Amarillo Biosciences, Inc. (ABI) is a diversified healthcare company engaged in the discovery and development of pharmaceutical and biotech products.

Ligand's Technologies Support and Enable Potential Coronavirus Treatments

Monday, February 3, 2020 - 1:30pm

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its proprietary technologies are being utilized by partners to support and enable potential treatments for the 2019 novel coronavirus, 2019-nCoV, that originated in Wuhan, China.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its proprietary technologies are being utilized by partners to support and enable potential treatments for the 2019 novel coronavirus, 2019-nCoV, that originated in Wuhan, China.
  • Technologies that have shown potential or general applicability in the antiviral or therapeutic antibody areas include Ligands Captisol, OmniAb and LTP (Liver-Targeted Prodrug) platforms.
  • OmniAb is a three-species transgenic-animal platform consisting of five different technologies used for producing mono- and bispecific human therapeutic antibodies.
  • 1 Holshue, et al., The New England Journal of Medicine, January 31, 2020: First Case of 2019 Novel Coronavirus in the United States.

Technological Advancements Expand Biopharmaceuticals' Production Capabilities

Friday, January 10, 2020 - 2:00pm

Viruses use the host's cells to replicate, therefore producing a harmless and effective antiviral drug is very complicated.

Key Points: 
  • Viruses use the host's cells to replicate, therefore producing a harmless and effective antiviral drug is very complicated.
  • Most antivirals are used for specific viral infections, while a broad-spectrum antiviral is effective against a wider range of viruses.
  • NV-HHV-101 was found to be safe in terms of potential genotoxicity in the suite of tests that were performed by an independent laboratory.
  • A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.